Skip to main content

A new way to access big pharma know-how and infrastructure.

At AstraZeneca, we love the passionate beat of collaboration and the unpredictable rhythm of innovation.

At the heart of the AstraZeneca site in Gothenburg, Sweden, we are proud to open up the BioVentureHub – giving emerging biotech/medtech companies and academic groups a unique opportunity to co-locate and interact with big pharma, and each other, to advance the life sciences.

As in a dance, we combine our styles, skills and embellishments to create something beautiful, passionate and endlessly exciting. With our expertise and experience we can lead - we love to lead. We’re equally happy to follow...

We know that we both have important things to contribute.

WHAT’S IN IT FOR YOU?

Embedded at the heart of AstraZeneca Gothenburg, you become part of a unique, open and collaborative scientific community. BioVentureHub members have the same access
to the facilities as AstraZeneca staff. 

Access to scientific leadership

Locating your business in the BioVentureHub at AstraZeneca Gothenburg, you can tap into the power of AstraZeneca’s world-class scientists and state-of-the art, ‘big pharma’ lab facilities and infrastructure.

Open doors and open innovation

AstraZeneca Gothenburg is an integrated discovery and development site built to facilitate open innovation and spontaneous interactions. AstraZeneca has invested heavily in open innovation, including access to compound libraries and screening technologies.

Growth

Being part of the BioVentureHub and co-locating with AstraZeneca helps you grow a stronger and more successful life science business. The road to market becomes less risky and costly.

A great place to work

As one of three strategic AstraZeneca R&D centres, and with a rich scientific heritage, AstraZeneca Gothenburg is more than just a great place to work. It is a vibrant, diverse and open environment in which you and your business can thrive.

A great place to live

With its seaside setting and close proximity to cultural and natural attractions, Gothenburg - the second largest city in Sweden – fully deserves all the recognition it gets as a top travel destination, and a clean, well-functioning place for you to live and enjoy. Check out the 'Move to Gothenburg' website.

Unique service offering

At the BioVentureHub, you get access to everything that AstraZeneca gets – from chemical supplies thru shared services and business support to rubber gloves. Our facilities live and breathe life science - everything about the site is optimised to enable business success.

Access to world-class scientific and technical skills

AstraZeneca Gothenburg features all the skills and capabilities you need to take drug projects from early discovery to launch. This includes everything from early medicinal chemistry and in vitro/vivo biology through drug safety and metabolism to pharmaceutical and clinical development.

Several specialised skills such as computational biology, transgenics, personal healthcare and biomarkers are represented at the site, to mention just a few. We also have specialised on-site expertise across the entire discovery and development value chain when it comes to respiratory/inflammation, autoimmunity, cardiovascular and metabolic diseases therapy areas - including a centre of excellence for inhalation.

“By acting in an environment with the competence and experience present at the BioVentureHub and AstraZeneca, we expect to reduce inherent development risks in the project and that our efforts will yield results much more quickly.”

- Henrik Nittmar, CEO of Corline Biomedical AB

How independently can you run your company in the BioVentureHub?

The BioVentureHub is a community of trust. We will ask you to enter into a basic rental agreement with AstraZeneca. The rental agreement defines facility-related rights and obligations, and includes a confidentiality policy. The rental agreement does not give AstraZeneca any rights to your company information nor to potential inventions/IP – not even a “first right of refusal”. As such, you have full freedom to operate as an independent company. No strings attached.

Would your company fit in?

Whether you are biotech, medtech, e-health, academia... the core principle permeating throughout the BioVentureHub is that you share a collaborative and open attitude built on mutual respect, innovation and scientific curiosity. 

The BioVentureHub is an ideal growth catalyst for companies that have just entered or are about to enter the development phase. 

Interested? Contact...

Magnus Björsne
AstraZeneca BioVentureHub
+46 70 846 70 86
magnus.bjorsne@astrazeneca.com

Established

AstraZeneca’s BioVentureHub was established in 2014 as an innovative ecosystem to further strengthen the life science industry in Scandinavia.

Collaboration

Ideal for emerging biotech and medtech businesses and academic groups. 18 companies, 1 academic group, 4 external sponsors, 2 scientific partners already onboard.

AstraZeneca

Approx. 2,800 m2 office & lab space in central site location. AstraZeneca Gothenburg employs approx. 2,600 people, including 600 Ph.D. scientists

Why is AstraZeneca doing this?

AstraZeneca set up the BioVentureHub to further strengthen the life science ecosystem in Scandinavia. Using resources and capacity in a new way, the hub exposes AstraZeneca to more innovation and science. It stimulates an even more vibrant place to work and generates future collaboration opportunities. More dance partners is a positive side effect!

“Combining different value chains, ideas and perspectives in the same place, our vision is to generate a climate of open innovation that will help grow and nurture the Scandinavian life science ecosystem.” 
- Magnus Björsne, AstraZeneca BioVentureHub

Meet the companies

Antaros

We enable decision-makers in clinical drug development to optimize outcomes and minimize risk in Phase 1b and Phase 2 trials by the use of advanced imaging techniques. We also provide expert support for product differentiation in life cycle management. We specialize in cardio-metabolic, respiratory, inflammatory and neuroscience conditions.
www.antarosmedical.com

Athera Biotechnologies

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, the fully human antibody PC-mAb, is in clinical development. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit.
www.athera.se

Cereno Scientific

Cereno Scientific is committed to intelligent thrombosis prevention. The company is developing an innovative pharmaceutical to strengthen the body's own intelligent defence system to prevent blood clots - to be used globally in the treatment of thrombosis-related cardiovascular diseases. www.cerenoscientific.com

Corline Pharma

Corline Pharma is a subsidiary to Corline Biomedical AB, a Nasdaq/OMX First North (CLBIO) listed company that develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Corline Pharma has been formed with the aim of exploring and evaluating new indications.

Emeriti Bio

Emeriti Bio AB is a privately held sister company to Emeriti Pharma AB. The focus is on novel treatment options for heavy menstrual bleeding. Emeriti Bio AB is also developing molecules for validated pharmaceutical drug targets in different areas. Finally, Emeriti Bio AB provides consultancy services in chemistry, drug discovery and drug development.

EmeritiPharma

Emeriti Pharma AB is a privately held sister company to Emeriti Bio AB. Emeriti Pharma is focused on the development of EP0003 for dermatology, a compound originally acquired from AstraZeneca. EP0003 will start phase I in Q3-2016. www.emeritipharma.se

ForValue

ForValue AB is a consultancy company in the medical devices area. Our consultants have long practical experience and broad, as well as specific, specialities that are combined in seamless solutions across competences (quality management, product development, clinical data, risk management, biocompatibility and the regulatory framework). 
www.forvalue.se

I-Tech

I-Tech, develops, manufacture and market an antifouling substance, Selektope. Selektope has proven remarkable fouling protection even in the most demanding situations and in very low concentrations in marine paints. Our vision is to be a global developer and supplier of marine biocides with an extended market share.
www.i-tech.se

Metabogen

Addressing the microbiome, MetaboGen is creating breakthrough opportunities to develop novel therapeutics and next generation probiotics. The company was founded based on world leading science from the labs of Professor Fredrik Bäckhed (University of Gothenburg) and Professor Jens B Nielsen (Chalmers University of Technology), to provide commercial access to metagenome research and development. www.metabogen.se

Metynex Pharmaceuticals

Metynex is a new company committed to the development of pharmaceuticals in the cardiometabolic area. The company has expertise in both preclinical and early clinical development in this therapeutic area. A new principle for treatment of type II diabetes is under development. The substance improves peripheral insulin sensitivity and also reduces the risk of the co-morbidities that are common in diabetics. 

NanoSIMS

Chalmers University of Technology/Gothenburg University have located their NanoSIMS laboratory in the BioVentureHub. The lab offers unique, ultra-high spatial chemical imaging giving true sub-cellular localisation of molecules in cells and tissue, as well as quantitative isotopic imaging for many other applications ranging from geology to materials science. 

Promimic

Promimic has developed a process that makes it possible to modify all types of implant materials and geometries with a nanometer-thin surface of synthetic bone minerals; HAnano Surface. It is based on the substance hydroxyapatite (HA)., which by size, shape, structure and chemistry mimics the living bone tissue. The HAnano Surface is licensed to dental and orthopaedic implants companies. Promimic is a spin-off company based on research from Chalmers University of Technology. www.promimic.com

Q&Q Labs

Q&Q Labs is a contract laboratory for custom research services within the field of organic analytical chemistry. Our main focus is to provide analysis services of active substances to producers of pharmaceuticals, medical device and food supplements. 
www.qandqlabs.se

Swecure

Swecure is focused on human development, with its lead candidate being a preventive treatment for allergy. The company is also developing a composition of bacteria shown to be lower in patients with IBD and IBS that work by modulating the human microbiome. Swecures products epitomize this: it uses good microbes to treat various diseases.
www.swecure.com

Synergon

Synergon offers qualified strategic IP advice and IP portfolio management, with a focus on protection of commercially viable IP, keeping costs at a minimum. We see the big picture around Intellectual Property (IP) from a business-oriented perspective within the Life Science, biotechnology and IT sectors. www.synergon.se

TATAA Biocenter

TATAA Biocenter is the world’s largest organizer of hands-on training in molecular analyses, Europe’s leading provider of nucleic acid analysis services, and Scandinavia’s most comprehensive distributor of products for nucleic acids analyses. Through its laboratories in Göteborg, Sweden, and Prague, Czech Republic, and sales office in Saarbrucken, Germany, TATAA Biocenter supports its clients with products for full range of nucleic acid and protein analyses and services in compliance with ISO17025 standard. www.tataa.com

Vicore Pharma

Vicore Pharma is a drug-development company at the cutting edge of international research on the AT2 receptor. The company’s portfolio comprises small molecules with clinical applicability in disease areas in need of anti-fibrosis, anti-inflammation, neuroprotection, neuroregeneration and cardiovascular protection.
www.vicorepharma.com

Vivolux

Vivolux focus is to develop new therapies in cancer. Vivolux has developed a pipeline of innovative drug candidates with new mode of actions. In 2014, Vivolux received US FDA IND approvals for two new drug candidates that have now entered clinical phase. The cutting-edge research has created a basis for cooperation with the leading cancer institutions in the USA.
www.vivolux.com

“AstraZeneca’s BioVentureHub has the potential to be a game changer for the Swedish life science industry.”
- Hans Rosén, CEO of Vivolux

Interested? Contact...

Magnus Björsne
AZ BioVentureHub AB
+46 70 846 70 86
magnus.bjorsne@astrazeneca.com

Our scientific partners

Sponsors